Initial cardiovascular treatment patterns during the first 90 days following an incident cardiovascular event

Tian-Tian Ma, Ian C. K. Wong, Cate Whittlesea, Isla S. Mackenzie, Kenneth K. C. Man, Wallis Lau, Ruth Brauer, Li Wei (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)
    78 Downloads (Pure)

    Abstract

    Aims: The aim of this study was to investigate the initial cardiovascular prescription patterns in patients after their first cardiovascular events, and to identify factors associated with cardiovascular polypharmacy.

    Methods: This was a cross-sectional study including patients aged ≥ 45 years with the first record of coronary heart disease (CHD) or stroke between 2007 and 2016 using The Health Improvement Network database. This study investigated the patterns of cardiovascular drugs prescribed during the first 90 days after the first cardiovascular events. Logistic regression was used to examine the association between patients' baseline characteristics and cardiovascular polypharmacy (≥5 cardiovascular drugs).

    Results: A total of 121,600 (59,843 CHD and 61,757 stroke) patients were included in the study. The mean age was 69.5 ± 11.9 years. The proportion of patients who were prescribed 0–1, 2–3, 4–5 drugs and ≥6 drugs were 11.0%, 29.8%, 38.6% and 20.5%, respectively. Factors associated with cardiovascular polypharmacy were sex (female: OR 0.74, 95% CI 0.72–0.76 vs male), age (75–84 years old: OR 0.50, 0.47–0.53 vs 45–54 years old), smoking status (current smoking: OR 1.29, 1.15–1.24 vs never), body mass index (obesity: OR 1.38, 1.34–1.43 vs normal), deprivation status (most deprived: OR 1.09, 1.04–1.14 vs least deprived) and Charlson comorbidity index (index ≥5: OR 1.25, 1.16–1.35 vs index 0).

    Conclusion: Multiple cardiovascular drugs treatment was common in patients with CVD in the UK. High-risk factors of CVD were also associated with cardiovascular polypharmacy. Further studies are warranted to assess the impact of cardiovascular polypharmacy and its interaction on CVD recurrence and mortality.

    Original languageEnglish
    Pages (from-to)1043-1055
    Number of pages13
    JournalBritish Journal of Clinical Pharmacology
    Volume87
    Issue number3
    Early online date9 Jul 2020
    DOIs
    Publication statusPublished - 2 Mar 2021

    Keywords

    • Coronary heart disease
    • stroke
    • cardiovascular drugs
    • polypharmacy
    • coronary heart disease

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Pharmacology

    Fingerprint

    Dive into the research topics of 'Initial cardiovascular treatment patterns during the first 90 days following an incident cardiovascular event'. Together they form a unique fingerprint.

    Cite this